Who NGI is, the expertise behind it, and where it is going.
NGI is a genomic laboratory in Indonesia and the local company of BGI Genomics. This page sets out who NGI is, the expertise behind it, what it is working toward, and the milestones that brought it here.
Who we are
Who we are.
NGI is the subsidiary company of BGI Genomics in Indonesia. We bring the science and technology of one of the world's leading genomics organizations into Indonesian healthcare, delivered by a team, laboratory and partner network based right here at home.
Everything we do follows one commitment: Omics for Indonesia. For us, that means making genomic testing accurate, affordable and accessible for every Indonesian, so families, clinicians and hospitals can make better health decisions earlier.
Commitment
Omics for Indonesia.
Global expertise
Global expertise, delivered locally.
As part of the BGI Genomics family, NGI builds on BGI's more than 25 years of experience in genome sequencing and clinical testing. We pair that global foundation with a deep understanding of Indonesia: our team knows the nation's health priorities, works within national regulations, and partners closely with local hospitals, clinics and institutions.
The first and only sequencer with a CE-IVD certificate in Indonesia.
- Accreditation
- ISO 15189 · CAP
- Laboratory
- Jakarta, Indonesia
Instruments in service
- DNBSEQ-G400
- Sequencer
- DNBSEQ-G99
- Sequencer
- DNBSEQ-E25
- Sequencer
- CYCLONESEQ-WT02
- Sequencer
- BGI LMSQ-1000
- Mass spectrometer
-
Proven technology
Our tests are built on BGI Genomics' sequencing platforms and clinical expertise, proven in healthcare settings around the world.
-
A laboratory in Jakarta
Our clinical laboratory is accredited to ISO 15189 and by the College of American Pathologists. It is also accredited by Indonesia's Minister of Health. It brings testing and analysis closer to the patients we serve.
-
Local partnerships
We work hand in hand with Indonesian hospitals, clinicians, patient foundations and research institutions to widen access to genomic care.
Vision and mission
Vision and mission.
Vision
To be a leading, integrated provider of omics-based healthcare solutions.
Mission
To deliver genomic services that are high in quality, competitively priced and easy to access across Indonesia.
NGI journey
NGI journey.
Ten milestones, from the company's founding in August 2022 to the CNV-seq technology transfer in October 2025.
- 2022
-
Aug 2022
NGI was founded
Founded as BGI Genomics' local company in Indonesia.
-
Nov 2022
G20 Summit, Bali
Participated in the G20 Summit and built a COVID-19 air laboratory in Bali, Indonesia.
- 2023
-
Feb 2023
Genomics laboratory inaugurated
Inaugurated by Indonesia's Ministry of Health and the BGI Group CEO.
-
Oct 2023
First NIPT run in the local laboratory
After completing the technology transfer from BGI, NGI began running NIPT testing locally.
- 2024
-
Mar 2024
COLOTECT technology transfer
The colorectal cancer early screening test completed technology transfer; NGI runs COLOTECT testing locally.
-
Jun 2024
HPV DNA testing technology transfer
HPV DNA testing completed technology transfer; NGI runs HPV DNA testing locally.
-
Jul 2024
PGT-A technology transfer
PGT-A completed technology transfer; NGI runs PGT-A testing locally.
-
Aug 2024
Thalassemia technology transfer
Thalassemia sequencing completed technology transfer; NGI runs thalassemia sequencing locally.
- 2025
-
Sep 2025
BGI-NGI multi-omics product launch
The BGI-NGI multi-omics product line was launched.
-
Oct 2025
CNV-seq technology transfer
CNV-seq completed technology transfer; NGI runs CNV-seq testing locally.